Remarkably, preclinical testing of HER-2-specific NK-92 cells (NK-92/5.28.z) in an orthotopic xenograft mouse model of glioblastoma demonstrated a dramatic increase in survival (200.5 days) compared to mice treated with control NK-92 cells (73 days) (139). This evidence concerns the gene ERBB2 and glioblastoma.